surufatinib

Overview

Surufatinib is a multi-kinase inhibitor targeting VEGFR2 (KDR), FGFR1, and CSF1R. It has anti-angiogenic and immunomodulatory activity and is evaluated in nasopharyngeal carcinoma (NPC) and other solid tumors.

Evidence in the corpus

• Surufatinib listed as an anti-angiogenic agent targeting VEGFR2 KDR in nasopharyngeal carcinoma, alongside apatinib, axitinib, and anlotinib as part of anti-angiogenic strategies in R/M NPC PMID:24952746.

Resistance mechanisms

Cancer types (linked)

• NPC

Sources

This page was processed by entity-page-writer on 2026-05-11.